A new study in the peer-reviewed medical journal The BMJ found that medical device makers have increasingly used summary reporting to disclose harms, despite the U.S. Food and Drug Administration saying it ended the practice years ago. The FDA has continued to allow summary reporting through exemptions that were not made public, the study found.
The study said the reports contained “incomplete, inaccurate, and delayed” information. Fifty-seven percent described an adverse event “without identified device or use problem,” 38 percent marked “insufficient information” in the device-problem field, and 11 percent incorrectly said a report contained only one adverse event, leading to an undercount of nearly 12,000 events.
Researchers analyzed 6,303 adverse-event reports filed under summary-reporting exemptions from July 2019 to June 2025. The reports covered 159,503 individual adverse events, almost all involving serious injury or death. The number of reports filed under the exemptions more than doubled, from 808 in 2020 to 1,757 in 2024.
The study found that almost all events in the summary reports involved cardiac devices, and more than 90 percent were associated with “Class 3” devices, the highest-risk category regulated by the FDA. Nine of the 13 devices granted exemptions have been recalled. The study said the recalls “may have been delayed because of the difficulties of identifying individual adverse event counts and narratives from summary reports.”
For decades, the FDA allowed manufacturers to submit quarterly spreadsheets through a program called “alternative summary reporting,” rather than filing incident reports individually. The International Consortium of Investigative Journalists’ 2019 Implant Files investigation found that this approach concealed severe injuries. The FDA ended the program in 2019, saying it was doing so “in the spirit of public transparency.”
Madris Kinard, a former FDA official and co-author of the study, said she first learned about the exemptions in 2019 and has filed Freedom of Information Act requests about them for years. On a call with ICIJ, she pointed to a summary report listing 4,445 deaths among patients using a heart implant designed to reduce stroke risk. The report says “multiple event terms may apply to a single patient.” “You can’t die more than once,” Kinard noted.
The Implant Files, which brought together more than 250 journalists in 36 countries, reported that from 2008 to 2017 more than 1.7 million injuries and nearly 83,000 deaths in the U.S. were suspected of being linked to medical devices.
The issue of device-data transparency drew renewed public attention last week, when The Boston Globe published an investigation into a heart implant that generates nearly $2 billion in annual sales for Boston Scientific. The company spent tens of millions of dollars on television advertising to consumers and paid doctors $30 million to promote the device and train other physicians. Doctors told the newspaper the implant is not more effective than blood thinners and warned it was being used with a broader group of patients than originally intended.
“If physicians cannot see broader safety patterns, researchers cannot independently investigate them, and manufacturers may have different access than regulators, who is responsible for connecting the dots when a safety signal emerges?” Kinard told ICIJ. “Is restricting access to timely, de-identified, device-specific safety information really in the public interest?”
